drugset / Trial / NCT07144254
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
Timeline
- Start
- 2026-01-22
- Primary completion
- 2028-05
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegavivint | Small molecule | 3 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 5 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 6.5 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |